Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 20/20 | 1.00 |
| ▸ | BCL2L1 | Q07817 | 16/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24775760 | 1.00 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL24775759 | 0.98 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL30658705 | 0.98 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL29855885 | 0.95 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL24776076 | 0.95 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL24775015 | 0.95 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL30658632 | 0.95 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL24775756 | 0.95 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL24774717 | 0.95 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 | |
| SCHEMBL30658669 | 0.95 | BCL2 (1.00) | BCL2BCL2L1CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | claimed |
| EP-4522169-A1 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | BeiGene Switzerland GmbH (CH) | 2025-03-19 | — | — | EP | claimed |
| WO-2023218410-A1 | METHODS OF TREATING MYELOID MALIGNANCIES USING BCL-2 INHIBITOR | BEIGENE SWITZERLAND GMBH (CH) | 2023-11-16 | — | — | WO | claimed |
| EP-4545515-A1 | BCL-2 INHIBITORS | BeiGene Switzerland GmbH (CH) | 2025-04-30 | — | — | EP | disclosed |